Proffitt & Goodson’s CorMedix CRMD Stock Holding History

Proffitt & Goodson’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-400	Closed	-$3.24K	–	263
2024 Q4	$3.24K	Buy	+400	New	+$4K	﹤0.01%	234

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Proffitt & Goodson's CRMD Position: Q1 2025 in Review

Proffitt & Goodson sold out of CorMedix (CRMD) in Q1 2025, closing a stake of 400 shares — an estimated $3.24K sold.

Proffitt & Goodson first reported a position in CRMD in Q4 2024 and held it in 1 quarter. The position peaked at $3.24K in Q4 2024. 137 funds tracked by Wall St. Rank hold CRMD as of Q1 2025.

Proffitt & Goodson reported no remaining CorMedix position as of Q1 2025 after selling out during the quarter.
Proffitt & Goodson sold 400 CorMedix shares in Q1 2025, an estimated $3.24K.
Proffitt & Goodson first reported a position in CorMedix in Q4 2024 and held it in 1 quarter.
Proffitt & Goodson's CorMedix position peaked at $3.24K in Q4 2024.
137 funds tracked by Wall St. Rank held CorMedix as of Q1 2025.

Based on Proffitt & Goodson's 13F filing for Q1 2025, filed 29 Apr 2025.